MedPath

Randomized Controlled Trial Intervention With New Nordic DIet in Women With GestatiOnal Diabetes Mellitus: iNDIGO

Not Applicable
Terminated
Conditions
Gestational Diabetes Mellitus
Interventions
Behavioral: New Nordic Diet
Other: Control
Registration Number
NCT04169243
Lead Sponsor
Göteborg University
Brief Summary

The study evaluates whether the New Nordic Diet, compared to routine care, will improve glucose control, among women developing gestational diabetes mellitus during pregnancy.

Originally, a 10 wk intervention with qualified counseling on New Nordic Diet was planned, and effects on glycosylated haemoglobin A (HbA1c) at gestational age 37 weeks was planned as main outcome. Recruitment started in spring 2020 but had to be halted due to covid-19. Instead, we now conduct a more comprehensive version of the study, with a more intensive intervention consisting of distributed food bags plus dietary counselling for two weeks, and with continuous glucose monitoring during these two weeks to measure main outcome. This is more sensitive to small changes than is HbA1c. With this shorter and more intensive intervention we believe we can address our original hypothesis yet adjust to impacts of the covid-19 situation on the population and health care system.

Detailed Description

Gestational diabetes mellitus (GDM) is associated with severe adverse outcomes for mother and newborn. Recently introduced Swedish guidelines on GDM diagnosis will at least double the prevalence of diagnosed women. The first line of treatment in GDM is diet and exercise treatment. Even so, there is a recognized knowledge gap as to what diet treatment is optimal. In routine care today, diagnosed women are provided by midwife with the same diet advice as patients with diabetes type 2 and these are broad and general. Only rarely are the diet advice provided by a dietician. In nutrition research, most evidence for health benefits of a diet has been demonstrated for the Mediterranean diet. Further, the New Nordic Diet (NND) was recently developed to mimic the Mediterranean diet yet builds on foods grown in the Nordic climate, thus focusing on gastronomical potential and sustainability. Interestingly, a diet intake in line with NND among Norwegian mothers was associated with lower risk for excessive pregnancy weight gain. In addition, associations have been shown between NND and lower risk for cardiovascular disease, obesity, inflammatory risk markers, serum lipids, colorectal cancer and total mortality. Hence, it seems likely that diet treatment with NND to women with GDM would be superior to routine care, but this has never been investigated. The main aim of the randomized controlled trial Intervention with new Nordic DIet in women with GestatiOnal diabetes mellitus (iNDIGO) is to test if the NND compared with usual care will improve glucose control in women with GDM. The iNDIGO study is a randomized parallel, single-blinded, controlled trial. In total, 50 women diagnosed with GDM are recruited and randomized to receive either a NND (intervention) or usual care (control) for 14 days. Participants receive a two-week menu and provided with food bags containing ingredients for dishes and foods to be used. Primary outcome is glycemic control (specifically time in target) measured using continuous glucose monitoring. Compliance to the dietary intervention will be tested using known dietary biomarkers and adherence questionnaires. Maternal socio-demographic and clinical data, biological samples, dietary intake and physical activity will be collected at enrollment and at the end of intervention (30-32 weeks' gestation).

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
5
Inclusion Criteria
  • pregnant women with diagnosis of gestational diabetes in pregnancy wks 24-28.
Exclusion Criteria
  • multiple pregnancies
  • not understanding/able to read Swedish or English
  • unwilling to follow a dietary intervention
  • manifest diabetes

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionNew Nordic DietWomen randomized to the New Nordic Diet meet the study dietician at week 30 for 1.5 hr of individual diet treatment according to the New Nordic Diet and a cognitive behavioral approach. The diet advice include evenly distributed meals over the day, foods low in fat and rich in fibre, 500 g fruit and vegetables daily, fish 2-3 times a week and keyhole foods. Participants will prepare their own food but are provided with recipes and food bags containing ingredients and foods to be consumed during the two-week intervention At gestational age 32 weeks, women meet with a dietitian and will be instructed to continue with the New Nordic Diet diet throughout pregnancy on their own.
ControlControlThe control women receive diet advice according to usual care.
Primary Outcome Measures
NameTimeMethod
Time in Target at gestational week 32At week 32 of pregnancy

Percentage of time in target (TIT) range 3.5-7.8 mmol/L measured with continuous glucose monitoring

Secondary Outcome Measures
NameTimeMethod
Incidence of pre-eclampsiaUp to delivery

Diagnosis of pre-eclampsia

Health-related quality of lifeUp to 1 year postpartum

Health-related quality of life, calculated from questionnaire information from RAND-36

Incidence of LGAAt delivery

Large-for-gestational age born infant

Apgar scores measurementsAt delivery

Apgar scores measured at 1, 5 and 10 minutes after delivery

Pregnancy weight gainPre-pregnant weight up to delivery

Weight gain during pregnancy from self-reported pre-pregnancy weight until delivery

Incidence of Caesarean sectionsUp to delivery

Delivery by caesarean sections

Nutritional statusDuring pregnancy

Nutritional status (vitamins and minerals) of mother during pregnancy

Diet quality measuremen¨tUp to delivery

Diet intake quality of mother during pregnancy

Prevalence of use of insulin/Metformin treatmentUp to delivery

Decision to put woman on medication for the gestational diabetes, such as metformin or insulin

Incidence of preterm deliveryUp to 37 completed weeks

Delivery before 37 completed weeks

Additional measurements from continuous glucose monitoring at wk 32At gestational week 32

mean glucose, CV, SD, MAGE, % time with values \>7.8 mmol/L, % time with values \<3.5 mmol/L, glucose in different time periods, and AUC

Incidence of pregnancy-induced hypertensionUp to delivery

Diagnosis of pregnancy-induced hypertension

Incidence of shoulder displacementAt delivery

Shoulder displacement of newborn infant

Additional measurements from continuous glucose monitoring at wk 36At gestational week 36

mean glucose, CV, SD, MAGE, % time with values \>7.8 mmol/L, % time with values \<3.5 mmol/L, glucose in different time periods, and AUC

Incidence of macrosomiaAt delivery

Diagnosis of macrosomia in newborn infant

Trial Locations

Locations (3)

Antenatal care

🇸🇪

Göteborg, Sweden

Region Stockholm

🇸🇪

Stockholm, Sweden

Region Västerbotten

🇸🇪

Umeå, Sweden

© Copyright 2025. All Rights Reserved by MedPath